Suppr超能文献

肝性脑病治疗管理的最新进展

Update on the Therapeutic Management of Hepatic Encephalopathy.

作者信息

Kornerup Linda Skibsted, Gluud Lise Lotte, Vilstrup Hendrik, Dam Gitte

机构信息

Department of Hepatology and Gastroenterology, Aarhus University Hospital, 44 Norrebrogade, 8000, Aarhus, Denmark.

Gastrounit, Medical Division, Copenhagen University Hospital, Kettegaard Allé 30, Hvidovre, 2650, Denmark.

出版信息

Curr Gastroenterol Rep. 2018 Apr 11;20(5):21. doi: 10.1007/s11894-018-0627-8.

Abstract

PURPOSE OF REVIEW

Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.

RECENT FINDINGS

Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.

摘要

综述目的

肝性脑病(HE)是慢性肝病常见且严重的并发症。在本文中,我们总结了传统治疗方法和新兴治疗方法的最新研究及证据。

最新发现

荟萃分析报告了乳果糖、支链氨基酸、利福昔明以及在一定程度上L-鸟氨酸L-天冬氨酸对肝硬化患者HE表现的有益作用,且通常治疗所需人数较少。近期关于包括鸟氨酸苯乙酸、球形碳和粪便微生物群移植等新型HE治疗方法的研究也报告了对HE表现可能有益的作用。传统治疗方法对HE患者有益。新型治疗方法正在研究中,需要更多研究来验证其效果。

相似文献

1
Update on the Therapeutic Management of Hepatic Encephalopathy.
Curr Gastroenterol Rep. 2018 Apr 11;20(5):21. doi: 10.1007/s11894-018-0627-8.
2
Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Metab Brain Dis. 2013 Jun;28(2):221-5. doi: 10.1007/s11011-012-9372-0. Epub 2012 Dec 29.
3
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Curr Opin Gastroenterol. 2019 May;35(3):145-154. doi: 10.1097/MOG.0000000000000527.
4
Prophylaxis of hepatic encephalopathy: current and future drug targets.
Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16.
5
Pharmacologic Management of Hepatic Encephalopathy.
Clin Liver Dis. 2020 May;24(2):231-242. doi: 10.1016/j.cld.2020.01.005. Epub 2020 Mar 2.
6
Management of hepatic encephalopathy in the hospital.
Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8.
7
Nontraditional Treatment of Hepatic Encephalopathy.
Clin Liver Dis. 2024 May;28(2):297-315. doi: 10.1016/j.cld.2024.01.007. Epub 2024 Feb 15.
8
Treatment of Overt Hepatic Encephalopathy.
Clin Liver Dis. 2015 Aug;19(3):551-63. doi: 10.1016/j.cld.2015.04.005. Epub 2015 May 30.
9
Pharmacologic Management of Hepatic Encephalopathy.
Clin Liver Dis. 2024 May;28(2):287-296. doi: 10.1016/j.cld.2024.01.006. Epub 2024 Feb 1.

引用本文的文献

2
Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis.
Front Neurosci. 2021 Mar 10;15:579263. doi: 10.3389/fnins.2021.579263. eCollection 2021.
3
A Case of Rapid Decline in Alcohol-Associated Liver Disease.
Clin Liver Dis (Hoboken). 2021 Feb 28;17(2):67-70. doi: 10.1002/cld.997. eCollection 2021 Feb.
5
The critical role of hippocampal dopamine in the pathogenesis of hepatic encephalopathy.
Physiol Res. 2021 Mar 17;70(1):101-110. doi: 10.33549/physiolres.934563. Epub 2021 Jan 14.
6
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
J Manag Care Spec Pharm. 2020 Jun;26(6):750-757. doi: 10.18553/jmcp.2020.26.6.750.
7
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.
World J Hepatol. 2019 Jun 27;11(6):489-512. doi: 10.4254/wjh.v11.i6.489.
8
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD012334. doi: 10.1002/14651858.CD012334.pub2.
9
Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease.
J Clin Exp Hepatol. 2018 Sep;8(3):262-271. doi: 10.1016/j.jceh.2018.08.001. Epub 2018 Aug 18.

本文引用的文献

1
Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Fundam Clin Pharmacol. 2018 Apr;32(2):209-215. doi: 10.1111/fcp.12340. Epub 2018 Jan 11.
3
L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
Hepatology. 2018 Feb;67(2):700-710. doi: 10.1002/hep.29410. Epub 2017 Dec 27.
4
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.
Hepatology. 2017 Dec;66(6):1727-1738. doi: 10.1002/hep.29306. Epub 2017 Oct 30.
7
Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.
Therap Adv Gastroenterol. 2016 Nov;9(6):823-835. doi: 10.1177/1756283X16658252. Epub 2016 Jul 26.
8
Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.
Hepatology. 2016 Sep;64(3):908-22. doi: 10.1002/hep.28598. Epub 2016 May 20.
10
Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia.
Semin Liver Dis. 2016 Feb;36(1):48-55. doi: 10.1055/s-0036-1571298. Epub 2016 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验